Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been assigned a consensus recommendation of “Hold” from the eleven ratings firms that are presently covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $4.79.

Separately, StockNews.com initiated coverage on Marinus Pharmaceuticals in a research note on Tuesday, March 18th. They set a “sell” rating for the company.

Institutional Trading of Marinus Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC boosted its stake in Marinus Pharmaceuticals by 32.8% during the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after purchasing an additional 1,253,901 shares during the period. Franklin Resources Inc. boosted its stake in Marinus Pharmaceuticals by 34.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after purchasing an additional 1,219,871 shares during the period. Beryl Capital Management LLC bought a new stake in Marinus Pharmaceuticals during the 4th quarter valued at approximately $2,262,000. Woodline Partners LP boosted its stake in Marinus Pharmaceuticals by 84.7% during the 4th quarter. Woodline Partners LP now owns 2,335,681 shares of the biopharmaceutical company’s stock valued at $1,250,000 after purchasing an additional 1,071,410 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Marinus Pharmaceuticals by 266.1% during the 4th quarter. JPMorgan Chase & Co. now owns 487,584 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 354,393 shares during the period. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Trading Down 0.2 %

MRNS opened at $0.55 on Monday. The stock has a market cap of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $9.41. The stock has a fifty day moving average price of $0.55 and a 200 day moving average price of $0.74.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.